Skip to main content
SpringerLink
Log in

PMDA highlights bleeding events with two antivirals

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. PMDA = Pharmaceuticals and Medical Devices Agency

References

  1. Pharmaceuticals and Medical Devices Agency of Japan. Summary of investigation results - Oseltamivir phosphate. Internet Document : [2 pages], 1 Mar 2019. Available from: URL: http://www.pmda.go.jp/files/000228453.pdf

  2. Pharmaceuticals and Medical Devices Agency of Japan. Summary of investigation results - Baloxavir marboxil. Internet Document : [2 pages], 1 Mar 2019. Available from: URL: http://www.pmda.go.jp/files/000228435.pdf

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

PMDA highlights bleeding events with two antivirals. Reactions Weekly 1744, 6 (2019). https://doi.org/10.1007/s40278-019-58905-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-58905-4

Search

Navigation